Unlock instant, AI-driven research and patent intelligence for your innovation.
2',3'-dihydrospiro[cyclopropane-1,1'-indene]-2-amine derivative as well as preparation method and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of amine derivatives and cyclopropane, applied in the field of medicine, can solve the problems of poor selectivity and low inhibitory activity
Inactive Publication Date: 2018-09-14
EAST CHINA NORMAL UNIV +1
View PDF3 Cites 4 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Among them, phenylcyclopropylamine is the most studied class of inhibitors. The disadvantages are low inhibitory activity and poor selectivity to homologous enzymes such as monoamine oxidase and LSD2.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0185] Example 1: Preparation of 2', 3'-dihydrospiro[cyclopropane-1,1'-indene]-2-amine (1)
[0186] (a) Preparation of 1-methylene-2,3-dihydro-1H-indene (1a)
[0187] 2,3-Dihydro-1H-inden-1-one (4.00g, 30.30mmol) and triphenylmethylphosphine bromide (16.24g, 45.45mmol) were added to 20mL THF, and the A solution of 1.0M potassium tert-butoxide in THF (45.45mL, 45.45mmol) was added to the liquid funnel, the reaction solution was stirred at room temperature for 16 hours, the solvent was removed in vacuo, and the residue was purified by silica gelchromatography (petroleumether / ethyl acetate=100:1 ) to afford 1a as a colorless oil, 3.42g (87%).
[0188] (b) Ethyl (trans)-2',3'-dihydrospiro[cyclopropane-1,1'-indene]-2-carboxylate (1b) and (cis)-2',3'-dihydro Preparation of ethyl spiro[cyclopropane-1,1'-indene]-2-carboxylate (1b')
[0194] Example 2: Preparation of (cis)-2',3'-dihydrospiro[cyclopropane-1,1'-indene]-2-amine (2)
[0195] The preparation method of 2 was the same as that of 1 in Example 1, except that 1c' (300 mg, 1.16 mmol) was used instead of 1c to obtain 2, a yellow solid, 213 mg (94%). 1 H NMR (400MHz, CD 3 OD)δ7.32(d,1H),7.27–7.18(m,2H),7.10–7.03(m,1H),3.21–3.06(m,1H),3.02–2.92(m,1H),2.88(dd ,1H),2.40–2.27(m,1H),1.99–1.94(m,1H),1.54–1.47(m,1H),1.43(t,1H). 13 C NMR (101MHz, CD 3 OD)δ147.5, 140.4, 128.7, 127.7, 126.3, 121.9, 36.6, 35.0, 33.1, 31.5, 15.7.
Embodiment 3
[0196] Example 3: Preparation of (trans)-N-(pyridine-3-methyl)-2',3'-dihydrospiro[cyclopropane-1,1'-indene]-2-amine (3)
[0197] 1 (50 mg, 0.26 mmol) was dissolved in 2.0 mL MeOH at room temperature and triethylamine (39 mg, 0.39 mmol) was added to give the free amine. Then nicotinaldehyde (28 mg, 0.26 mmol) was added to the solution, stirred magnetically for 30 min, 4A molecular sieves were added, stirred for 15 min, sodiumborohydride (20 mg, 0.52 mmol) was added, and reacted for 16 hours. The mixture was then filtered and the solvent removed in vacuo to give the crude product, dissolved in ethyl acetate, saturated NaHCO 3 Wash, collect the organic phase, anhydrous Na 2 SO 4 It was dried, filtered and concentrated in vacuo, and purified by silica gelcolumn chromatography (petroleumether / ethyl acetate=4:1) to give 3, yellow oil, 26 mg (40%). 1 H NMR (400MHz, CD 3 OD)δ8.47(d,1H),8.42–8.37(m,1H),7.82–7.76(m,1H),7.35(dd,1H),7.16–7.10(m,1H),7.07–7.02(m ,2H),6.62–6.57(m,1H)...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention belongs to the technical field of medicine and discloses a 2',3'-dihydrospiro[cyclopropane-1,1'-indene]-2-amine derivative of a formula (I) as well as a preparation method thereof. The preparation method comprises the following steps: performing Witting reaction on II to obtain III, catalyzing cyclopropanation reaction of ethyl diazoacetate and the III by rhodium acetate to obtain IVand V, performing hydrolysis, performing Curtius rearrangement to obtain VI and VII; (1) removing Boc from the VI or VII and performing reduction and ammoniation to obtain a compound VIII or IX; or (2) performing substitution on the VI or VII and 2-chlorine-1-morpholine ethane-1-ketone to obtain X or XI; or (3) performing reduction and ammoniation on the VI or VII and (4-oxycyclohexyl)tert-butylcarbamate, and removing Boc to obtain a compound XII or XIII; or (4) performing Suzuki coupling on the VI or VII and substituted arylboronic acid, removing Boc to obtain XIV or XV, and performing reduction and ammoniation to obtain VIII or IX. The derivative of the formula (I) has high inhibition activity, has high selectivity on homologous enzyme such as monoamine oxidase and LSD2, and is expected to be developed into a medicine for treating diseases such as acute myelogenous leukemia.
Description
technical field [0001] The invention belongs to the technical field of medicine, and relates to a 2',3'-dihydrospiro[cyclopropane-1,1'-indene]-2-amine derivative and its preparation method and application, which can be used as a selective LSD1 inhibitor For the preparation of drugs for the treatment of acute myeloid leukemia. Background technique [0002] Acute myeloid leukemia (AML) is a heterogeneous malignant tumor in hematopoietic tissue, characterized by abnormal proliferation of primitive and immature myeloid cells in bone marrow and peripheral blood, clinical manifestations are anemia, hemorrhage, infection and fever, visceral Infiltration, abnormal metabolism, etc. Most cases are acute and severe, and the prognosis is dangerous. If not treated in time, it can often be life-threatening. The prevalence of AML is 3.8 cases per 100,000 people, increasing to 17.9 cases per 100,000 people over the age of 65. The standard treatment paradigm for AML has changed little in o...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.